▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1207 by analyst upside · 2026-09-27
KROS
Keros Therapeutics, Inc.
Healthcare · Market Cap $230M · P/E 0x
ANALYST PRICE TARGET
+70.7%
implied upside to consensus target
Current Price $11.62
Consensus Target $19.83
Bull Target $25.0
Bear Target $16.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
3
Hold
3
Sell
0
52-Week Low $9.69
52-Week High $22.55
YTD Return -37.3%
FUNDAMENTALS
Market Cap $230M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.22
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $15M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $9.69
52-Week High $22.55
Current Price $11.62
Bear Target $16.0
Bull Target $25.0
● Now $11.62 ● Target $19.83
TRADING DATA
Avg Volume 210K
YTD Return -37.3%
Analyst Count 6
Consensus Buy
Upside to Target +70.7%
Last Updated 2026-09-27

ANALYST SUMMARY

Keros Therapeutics, Inc. (KROS) is currently trading at $11.62 with a Wall Street consensus price target of $19.83, implying potential upside of 70.7% over the next 12 months. 6 analysts currently cover KROS, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $25.0, while the most cautious has a target of $16.0.

KROS operates in the Healthcare sector with a market capitalisation of $230M. The stock is down 37.3% year-to-date and is currently trading near the lower end of its 52-week range of $9.69 – $22.55.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CGEN +93.3%
Compugen Ltd.
$225M · P/E 6.3x · Buy
ORMP +48.0%
Oramed Pharmaceuticals Inc.
$197M · P/E 1.1x · Hold
ELMD +74.0%
Electromed, Inc.
$233M · P/E 21.4x · Buy
WW +97.4%
WW International, Inc.
$144M · P/E 1.6x · Hold
PDEX +3.1%
Pro-Dex, Inc.
$230M · P/E 17.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for KROS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo - Reiterated
Overweight → Overweight 2026-08-04 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-08-04 29% win rate (7 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-03-05 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2025-11-28 Building track record
Oppenheimer reit
Outperform → Outperform 2025-11-12 14% win rate (7 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2025-11-11 Building track record
Wedbush - Reiterated
Neutral → Neutral 2025-11-06 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-08-08 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
37
out of 100
Coverage depth
15/30
Consensus clarity
15/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →